Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/33816
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Goette, Andreas | - |
dc.contributor.author | VRANCKX, Pascal | - |
dc.date.accessioned | 2021-04-02T12:02:27Z | - |
dc.date.available | 2021-04-02T12:02:27Z | - |
dc.date.issued | 2020 | - |
dc.date.submitted | 2021-03-02T10:05:41Z | - |
dc.identifier.citation | EUROPEAN HEART JOURNAL SUPPLEMENTS, 22 (I) , p. I22 -I31 | - |
dc.identifier.uri | http://hdl.handle.net/1942/33816 | - |
dc.description.abstract | About 20% of all atrial fibrillation (AF) patients develop coronary artery disease, which requires coronary stenting [percutaneous coronary intervention (PCI)]. Thus, this subcohort of AF patients may require aggressive antithrombotic therapy encompassing vitamin K antagonist (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) plus aspirin and a P2Y12 inhibitor. At present, four clinical Phase IIIb trials using dabigatran, rivaroxaban, apixaban, or edoxaban, were published. These studies assessed the impact of NOACs as a part of DAT therapy vs. triple therapy. Compared with triple therapy, NOAC-based DAT has been shown to be associated with reduced major bleeding as well as intracranial haemorrhages. The benefit, however, is somewhat counterbalanced by a higher risk of stent-related ischaemia during the early phase of dual therapy. Thus, triple therapy after stenting is appropriate for at least 14 days with a maximum of 30 days. Thereafter, DAT including a NOAC is the therapy of choice in AF PCI patients to reduce the risk of bleeding during a 1 year of follow-up compared to VKA-based regimes. The present review summarizes the published study results and demonstrates differences in trial design and reported outcomes. | - |
dc.description.sponsorship | Research grant from the Josef-Freitag-Stiftung Paderborn and Deutsche Herzstiftung. This paper was published as part of a supplement financially supported by an unrestricted educational grant from Daiichi Sankyo Europe GmbH. | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.rights | The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com | - |
dc.subject.other | Atrial fibrillation (AF) | - |
dc.subject.other | Atrial fibrillation (AF) | - |
dc.subject.other | Percutaneous coronary inter- vention (PCI) | - |
dc.subject.other | Percutaneous coronary intervention (PCI) | - |
dc.subject.other | Antithrombotic therapy | - |
dc.subject.other | Antithrombotic therapy | - |
dc.subject.other | Triple therapy | - |
dc.subject.other | Triple therapy | - |
dc.subject.other | Non-vitamin K antagonist oral anticoagulant | - |
dc.subject.other | Non-vitamin K antagonist oral anticoagulant | - |
dc.subject.other | NOAC | - |
dc.subject.other | NOAC | - |
dc.subject.other | Review | - |
dc.subject.other | Review | - |
dc.title | Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | I31 | - |
dc.identifier.issue | I | - |
dc.identifier.spage | I22 | - |
dc.identifier.volume | 22 | - |
local.format.pages | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Goette, A (corresponding author), St Vincenz Hosp, Paderborn, Germany.; Goette, A (corresponding author), Univ Hosp Magdeburg, Working Grp Mol Electrophysiol, Magdeburg, Germany.; Goette, A (corresponding author), Atrial Fibrillat Network AFNET, Munster, Germany. | - |
dc.description.notes | andreas.goette@vincenz.de | - |
dc.description.other | Goette, A (corresponding author), St Vincenz Hosp, Paderborn, Germany ; Univ Hosp Magdeburg, Working Grp Mol Electrophysiol, Magdeburg, Germany ; Atrial Fibrillat Network AFNET, Munster, Germany. andreas.goette@vincenz.de | - |
local.publisher.place | GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1093/eurheart/suaa101 | - |
dc.identifier.isi | WOS:000614662700005 | - |
local.provider.type | wosris | - |
local.uhasselt.uhpub | yes | - |
local.description.affiliation | [Goette, Andreas] St Vincenz Hosp, Paderborn, Germany. | - |
local.description.affiliation | [Goette, Andreas] Univ Hosp Magdeburg, Working Grp Mol Electrophysiol, Magdeburg, Germany. | - |
local.description.affiliation | [Goette, Andreas] Atrial Fibrillat Network AFNET, Munster, Germany. | - |
local.description.affiliation | [Vranckx, Pascal] Hasselt Univ, Dept Cardiol & Intens Care Med, Fac Med & Life Sci, Jessa Ziekenhuis, Hasselt, Belgium. | - |
local.uhasselt.international | yes | - |
item.fullcitation | Goette, Andreas & VRANCKX, Pascal (2020) Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants. In: EUROPEAN HEART JOURNAL SUPPLEMENTS, 22 (I) , p. I22 -I31. | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
item.contributor | Goette, Andreas | - |
item.contributor | VRANCKX, Pascal | - |
item.validation | ecoom 2022 | - |
crisitem.journal.issn | 1520-765X | - |
crisitem.journal.eissn | 1554-2815 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
suaa101.pdf | Published version | 768.8 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
3
checked on Oct 4, 2024
Page view(s)
22
checked on Jul 20, 2022
Download(s)
6
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.